Future Regulatory Medicinal Product’s Improvements

Globally, many nations have been working to improve the regulatory guidelines for medicinal products. In the US, the 1962 Food, Drug and Cosmetic Act, gave the US food and Drug Administration (FDA) the power to control the pre-market and post-market products (FDA, 2005). The new FDA power also became the catalyst and makes the FDA a highly scrutinized and criticized government agency, especially when a medicinal product has serious adverse events post-product approval by the FDA. The overwhelming blames that goes to the FDA when such an unfortunate event happens, puts the organization in more cautious and conservative status, in the approval process for new drugs or products (Hamrell, & Dombey, 2012). Furthermore, the biggest bottle neck facing the FDA is the lack of manpower in overseeing new drug reviews and officiating efficient approval of safer new drugs. In 1970’s, there is growing discontent in the FDA’s lag process for

This content is restricted to site members. If you are an existing user, please login. New users may register below.

Existing Users Log In